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Although human immunodeficiency virus type 1 (HIV-1) clade C continues to dominate the pandemic, only
two infectious clade C proviral DNA clones have been described (N. Mochizuki, N. Otsuka, K. Matsuo, T.
Shiino, A. Kojima, T. Kurata, K. Sakai, N. Yamamoto, S. Isomura, T. N. Dhole, Y. Takebe, M. Matsuda, and
M. Tatsumi, AIDS Res. Hum. Retrovir. 15:1321–1324, 1999; T. Ndung’u, B. Renjifo, and M. Essex, J. Virol.
75:4964–4972, 2001). We have generated an infectious molecular clone of a pediatric clade C strain, HIV1084i,
which was isolated from a Zambian infant infected either intrapartum or through breastfeeding. HIV1084i is
an R5, non-syncytium-inducing isolate that bears all known clade C signatures; gag, pol, and env consistently
mapped within clade C. Interestingly, gag resembled Asian isolates, whereas pol and env resembled African
isolates, indicating that HIV1084i probably arose from an intraclade recombination. As a recently transmitted
clade C strain, HIV1084i will be a useful vaccine development tool.
Human immunodeficiency virus type 1 (HIV-1) genetic di-
versity is reflected by three groups (M, N, and O), at least nine
group M clades, and 14 circulating recombinant forms (16).
Given the high error rate of its reverse transcriptase and the
potential for coinfecting clades to recombine, HIV has great
potential for diversifying (18). Currently, clade C viruses ac-
count for 56% of all global HIV infections (2).
Rapidly expanding within regions with a high prevalence of
HIV, such as sub-Saharan Africa, HIV clade C is considered to
be a more virulent circulating form than other clades (2, 18). In
general, clade C long terminal repeats (LTRs) contain three
NF-B sites compared to clade B LTRs, which contain only
two, a characteristic which was postulated to enhance clade C
proviral transcriptional activation (10). Indeed, the level of
tumor necrosis factor alpha stimulation correlated with the
number of NF-B sites, indicating some difference among HIV
LTRs (5, 20).
To date, numerous HIV isolates have been cloned and se-
quenced (3, 7–9, 11–15, 17–19, 21, 22). Among these, only
Indie-C1 (9) and MJ4 (12) are infectious clade C viruses that
use CCR5 as coreceptor. Indie-C1 is a primary Indian isolate
(9), and MJ4 is a chimeric infectious clone, containing the
96MOLE1 envelope and the replication-incompetent back-
bone of 96BW06. 96MOLE1 and 96BW06 were originally iso-
lated from anonymous infected donors in Botswana (12). The
HIV disease stages of the source persons for both Indie-C1
and MJ4 are unknown (9, 12).
We constructed a replication-competent, infectious proviral
DNA clone of a pediatric HIV clade C isolate, HIV1084i. This
virus was recovered by cocultivation from a 4-month-old, HIV-
positive Zambian infant whose umbilical cord blood had been
HIV negative by PCR. HIV-negative donor peripheral blood
mononuclear cells (PBMCs) were purified by using Lym-
phoprep (Life Technologies, Grand Island, N.Y.) and propa-
gated in RPMI 1640 medium containing 10% heat-inactivated
fetal bovine serum (FBS) and 5 g of phytohemagglutinin
(PHA) (Sigma, St. Louis, Mo.)/ml for 40 h. Then, the infant’s
PBMCs were cocultured with an equal number of PHA-stim-
ulated PBMCs from the seronegative donor to a combined
final concentration of 2  106 cells/ml. Equal numbers of fresh
uninfected PHA-stimulated PBMCs were added to the culture
weekly. Virus production was monitored by measuring HIV-1
p24 antigen levels with a commercial enzyme-linked immu-
nosorbent assay (ELISA) kit (Beckman Coulter, Somerset,
N.J.).
Genomic DNA from the cocultivated PBMCs served as tem-
plate for the following PCRs. A 5.4-kb fragment extending from
the 5 LTR through the vpr open reading frame was amplified
by using Expand High Fidelity Taq polymerase (Roche, Ala-
meda, Calif.) and the following Indie-C1-based primers: 5-
LTR-NotI (primer 1 in Fig. 1: 5-AATGCGGCCGCCTGGA
AGGGTTAATTTACTCCAAGAAAAGGCAAG-3) and 5-
reverse-AscI (primer 2 in Fig. 1: 5-GTCTATGAAACATAT
GGCGCGCCTTGGACAGGAGTCG-3) (Invitrogen, Carls-
bad, Calif.). Similarly, a 4.3-kb fragment extending from the
vpr open reading frame beyond the 3 LTR was amplified using
the following Indie-C1-based primers: 3-forward-AscI (primer
3 in Fig. 1: 5-CGACTCCTGTCCAAGGCGCGCCATATGT
TTCATAGAC-3) and 3-LTR-NotI (primer 4 in Fig. 1: 5-
CGCGCGGCCGCACTGACTAAAAGGGTCTGAGGGAT
CTCTAGTTAC-3) (Invitrogen). As indicated, NotI restric-
tion sites were added upstream of the 5 LTR and downstream
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of the 3 LTR, while an AscI restriction site was introduced
in the vpr open reading frame using the following nucleotide
changes: G5672C, A5674C, T5675G, and A5676C.
The amplicons were individually cloned into pCR 2.1-Topo
TA cloning vectors (Invitrogen) and expanded through trans-
formation of chemically competent Top 10 Escherichia coli
cells (Invitrogen). Plasmid DNA was extracted with the QIA-
prep Spin Miniprep kit (QIAGEN, Valencia, Calif.); full-
length proviruses were reconstructed from the subgenomic
segments. Briefly, all vectors were digested with XhoI and AscI
(New England Biolabs, Beverly, Mass.), and the 5 and 3
vectors (vectors B and C in Fig. 1) were subsequently treated
with alkaline phosphatase. The 3 insert (vector D in Fig. 1)
was treated with SpeI, and the 5 insert (vector A in Fig. 1) was
left unmodified. Overnight ligation of gel-purified vectors A
and C (or vectors D and B) (Fig. 1) with T4-DNA ligase was
followed by transformation of chemically competent Top 10F
E. coli cells (Invitrogen).
Next, 293T cells grown in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% FBS (Sigma) were transfected
with 6 g of HIV1084i DNA by calcium phosphate precipita-
tion (Promega, Madison, Wis.).
pIndie-C1 served as a positive control, and pIRES-hrGFP
(Life Technologies) served as a negative control. Cell-free su-
pernatants that were positive for p24 Gag ELISA (Beckman
Coulter) 72 h posttransfection were used to infect human
PBMCs. Supernatants were monitored every 3 days until day
15 for p24 Gag production; HIV1084i replication peaked on
day 9 (data not shown).
Next, we assessed the sensitivity of HIV1084i to zidovudine
(AZT). Half of the wells containing PBMCs were pretreated
with 10 M AZT (Sigma) for 30 min at 37°C. HIV1084i or
Indie-C1 were added and incubated overnight at 37°C; controls
included uninfected PBMCs cultured with AZT. The next day,
cells were washed three times with medium and resuspended in
RPMI medium supplemented with 15% FBS with or without
10 M AZT. Supernatants were collected at regular intervals.
Wells containing AZT did not produce p24. PBMCs from
three independent donors supported replication of HIV1084i
(Fig. 2 and data not shown), and HIV1084i env-specific prim-
ers were used to amplify a 700-bp fragment from genomic
DNA of infected PBMCs (data not shown).
To determine coreceptor usage, the following U87.CD4
cells expressing one of the following chemokine coreceptors
were used (1, 6): CCR1, CCR2b, CCR3, CXCR4, or CCR5,
as well as Ghost.CD4 cells expressing the CCR5, BOB, or
BONZO coreceptors (National Institutes of Health AIDS Re-
search and Reference Reagent Program, Rockville, Md.). The
cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS and infected with HIV1084i viral
stock in polybrene (Sigma). Supernatants were collected on
days 3, 5, 7, and 10 for p24 Gag titration. HIV1084i replicated
only in the U-87.CD4.CCR5 cells (p24 Gag levels, 1 ng/ml;
data not shown).
The infectious molecular clone of HIV1084i was sequenced
by using a primer walking method and more than 50 pIndie-
C1-derived primers. Individual contiguous stretches of proviral
DNA were assembled using the DNASIS program. HIV1084i
is 9,665 bp in length, and all reading frames for major and
accessory genes are open. Both LTRs are flanked by NotI
restriction sites, and vpr contains an AscI restriction site not
found in pIndie-C1. Although Vpr contained two nonconser-
vative mutations (D52A and T53P), HIV1084i productively
infected PBMCs from three independent donors.
To perform phylogenetic analysis, a multiple sequence align-
ment was carried out on gag, pol, and env and the expected Vpu
and Rev sequences with Clustal X (version 1.81) (Fig. 3).
Comparison of HIV1084i gag, pol, and env genes with those
of other HIV isolates placed HIV1084i within the clade C
lineage, despite having origins in Zambia, where the domi-
nant circulating HIV forms include clades C, D, and G; group
FIG. 1. Strategy for the cloning of HIV1084i. Full-length HIV1084i
was constructed from two subgenomic amplicons containing NotI and
AscI restriction sites at alternate ends of the molecule. NotI restriction
sites were added to the LTR primers (1 and 4), while AscI restriction
sites were introduced into primers 2 and 3, which spanned the vpr open
reading frame. Subcloning the PCR product into pCR 2.1 Topo clon-
ing vectors, followed by bacterial amplification, restriction endonucle-
ase-mediated linearization, and subsequent ligation yielded the 14.7-
kb proviral plasmid, HIV1084i.
FIG. 2. Kinetics of replication of HIV1084i and Indie-C1 in
PBMCs with or without AZT. PBMCs with or without 10 M AZT
were infected with excess HIV1084i or HIV Indie-C1. Supernatants
were collected at various days postinfection and analyzed by p24 Gag
ELISA. The figure depicts the average of results from two independent
experiments.
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O; and A/C and B/C recombinants (Fig. 3A to C) (4, 23).
HIV1084i had no evidence of interclade recombination; how-
ever, HIV1084i pol and env clustered closely with AF110963, a
Botswana isolate (Fig. 3B and C), while HIV1084i gag clus-
tered with two Indian and two Chinese isolates (AF067254 and
AB023804 and AF286229 and AF286230, respectively) (Fig.
3A). It is important to note that this differential clustering
could not have resulted from our cloning strategy (Fig. 1), as
the entire gag-pol region was contained within the 5 half that
was initially amplified en bloc using primers located within the
5 LTR and in vpr at the AscI restriction site (nucleotides 5670
to 5671). Thus, the recombination breakpoint region within the
gag-pol overlap region (nucleotides 2058 to 2253) was left un-
touched. We conclude that the differential clustering of gag
and pol within HIV1084i probably resulted from an intraclade
recombination event.
The predicted HIV1084i Rev and Vpu sequences revealed
several clade C signature sequences. Vpu contained the ARVDY
sequence, a 5-amino-acid (aa) extension upstream of the ami-
no-terminal transmembrane domain (Fig. 3D). This extension
was also present in Vpu of MJ4, a hybrid constructed from two
distinct African clade C isolates; however, it was absent from
Indie-C1 and the non-C isolates examined, as reported previ-
ously (19). Furthermore, the clade C-specific LRLL motif ap-
peared upstream of the Vpu C terminus for HIV1084i, MJ4,
and Indie-C1 but was absent from all other non-C infectious
clones. Phylogenetic analysis placed HIV1084i Vpu into the
clade C cluster as a branch off the MJ4 lineage (Fig. 3D).
Compared to the clade B reference, HBX-2R, the Rev aa
sequences for HIV1084i, MJ4, and Indie-C1 contained prema-
ture stop codons, which shortened HIV1084i and MJ4 by 9 aa
and Indie-C1 by 16 aa (Fig. 3E). Phylogenetic analysis of the
HIV1084i Rev localized it within the clade C cluster, as a
branch of the MJ4 lineage (Fig. 3E).
Next, we surveyed the number of NF-B binding sites found
in 16 distinct clade C LTRs. HIV1084i and eight other LTRs
contained three NF-B binding sites, two of which contained
the sequence GGGACTTTCC, while the third site’s sequence
FIG. 3. Phylogenetic analysis of gag, pol, env, Vpu, and Rev. Using Clustal X (version 1.81) followed by PAUP (version 4.0), unrooted boot-
strapped phylogenetic trees were generated for gag (A), pol (B), env (C), Vpu (D), and Rev (E) of HIV1084i. One thousand bootstrap replicates, a
gap opening penalty of 50 (or 10), a gap extension penalty of 5 (or 0.1), and the International Union of Biochemistry DNA (or Gonnet 250 protein)
weight matrix were used to generate the trees. Only bootstrap values greater than 70 are indicated. All reference DNA sequences were obtained
from the Los Alamos National Laboratory HIV database (http://hiv-web.lanl.gov/). 93IN101 (AB023804) is referred to herein as Indie-C1 (9).
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was GGGGCGTTCC. The remaining seven LTRs, including
that of MJ4 (12), displayed two of the three characteristic
NF-B binding sites with the sequence GGGACTTTCC.
In conclusion, we have constructed an infectious molecular
clade C clone, HIV1084i, which was replication competent in
PBMCs from three different donors, was exclusively R5 tropic,
and did not induce syncytia. Isolated from a Zambian infant
whose infection was first detected by PCR at 4 months of age,
HIV1084i represents a recently transmitted virus. Consistent
with recent transmission, many viral isolates recovered from
the 1084 mother-infant pair had uncharacteristically close env
sequence homology (25). As a recently transmitted virus,
HIV1084i will be a useful tool for testing novel passive (24)
and active vaccine strategies.
Nucleotide sequence accession number. The nucleotide se-
quence of HIV1084i is available through GenBank (no.
AY805330).
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